Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MS417 (GTPL7512) is an inhibitor of BET-specific BRD4(BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM, respectively), with weak selectivity at CBP BRD with IC50 of 32.7 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
2 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 195.00 | |
50 mg | In stock | $ 297.00 | |
100 mg | In stock | $ 513.00 |
Description | MS417 (GTPL7512) is an inhibitor of BET-specific BRD4(BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM, respectively), with weak selectivity at CBP BRD with IC50 of 32.7 μM. |
Targets&IC50 | CBP BRD:32.7 μM, BRD4 BD2:46 nM , BRD4 BD1:30 nM |
In vivo | BET (Bromodomain and Extra-Terminal domain)-specific bromodomain inhibitor MS417, designed to block BRD4 binding to the acetylated NF-κB, effectively attenuates NF-κB transcriptional activation of proinflammatory genes in kidney cells treated with TNFα or infected by HIV.?MS417 ameliorates inflammation and kidney injury in HIV-1 transgenic mice, an animal model for HIVAN[1]. |
Synonyms | GTPL7512 |
Molecular Weight | 414.91 |
Formula | C20H19ClN4O2S |
CAS No. | 916489-36-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 50 mg/mL (120.51 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MS417 916489-36-6 Chromatin/Epigenetic Microbiology/Virology Proteases/Proteasome HIV Protease Epigenetic Reader Domain GTPL7512 inhibit HIV GTPL-7512 GTPL 7512 Inhibitor MS-417 MS 417 Human immunodeficiency virus inhibitor